

---

**From:** Beckhardt, Stacey </O=CEPHALON/OU=US01 ADMINISTRATIVE GROUP/CN=RECIPIENTS/CN=SBECKHAR>  
**To:** Yeh, Helen; Messina, John  
**CC:** Merritt, Chip; Grupp, Robert; Williams, Sheryl; Clements, Sean; 'lweiss@cooneywaters.com'; ccollier@cooneywaters.com; Castagno, Paula; Richardson, Michael; Terifay, Terrence; Napoletano, Matthew; Winkelman, Dan  
**Sent:** 1/5/2007 5:00:10 PM  
**Subject:** FW: APS 2007  
**Attachments:** APS FBT 30412 dose correlation FINAL 27 oct 06.doc; APS 3040 1 2 pt preference Actiq switch\_FINAL 27 oct 06.doc; APS 3040 pt pref\_FINAL 27 OCT 06.doc; APS Abstract\_3040 POMSSF36\_FINAL 27 oct 06.doc; APS\_3041 3042combined efficacy\_FINAL 27 oct 06.doc; APS\_3041\_3042comp\_FINAL 27 oct 06.doc

Congratulations! We will continue to develop and implement our PR strategy to support this meeting. Stacey

Stacey Beckhardt

Associate Director, Public Relations

Cephalon, Inc.

41 Moores Road

Frazer, PA 19355

sbeckhar@cephalon.com

610-738-6198 (telephone)

610-344-0981 (fax)

---

**From:** Yeh, Helen  
**Sent:** Friday, January 05, 2007 11:57 AM  
**To:** Terifay, Terrence; Messina, John; Richardson, Michael; Xie, Fang; Narayana, Arvind  
**Cc:** Beckhardt, Stacey; Shah Bell, Bhaval; Sehgal, Arpana; Thatcher, Jerri Ann  
**Subject:** APS 2007



Dear all

Good news ..... all six of our abstracts have been accepted for poster presentation at APS, 2-5 May, 2007, Washington DC.

The list is as follows; copies of the abstracts are attached.

- 3040 (interim) – Patient Preference for Fentanyl Buccal Tablet (FBT) in the Management of Breakthrough Pain: Open-Label Evaluation in Opioid-Tolerant Patients With Chronic Noncancer Pain. Srinivas Nalamachu, MD; Fang Xie, PhD; John Messina, PharmD
- 3040 (interim) – Mood, Functioning, and Quality of Life in Opioid-Tolerant Patients with Noncancer Chronic Pain and Breakthrough Pain: Effect of Fentanyl Buccal Tablet (FBT). Srinivas Nalamachu, MD; Fang Xie, PhD; John Messina, PharmD
- 3041+3042 – Lack of Correlation Between Doses of Fentanyl Buccal Tablet (FBT) and Opioids Used to Treat

Persistent and Breakthrough Pain. Gerald M. Aronoff, MD, FAADEP; John Messina, PharmD; Fang Xie, PhD; John F. Peppin, DO, FACP

- 3041+3042 – Management of Breakthrough Pain (BTP) in Opioid-Tolerant Patients with Chronic Low Back Pain or Neuropathic Pain: Combined Analysis of Two Randomized, Double-Blind Studies of Fentanyl Buccal Tablet (FBT). Perry Fine, MD; John Messina, PharmD; Fang Xie, PhD; John F. Peppin, DO, FACP
- 3041 vs 3042 – Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Low Back Pain or Neuropathic Pain: Randomized, Double-Blind Studies of Efficacy and Tolerability of Fentanyl Buccal Tablet (FBT). David Simpson, MD; John Messina, PharmD; Fang Xie, PhD; Martin Hale, MD
- 3040+3041+3042 – Multi-Study Analysis of Patients' Preference for Fentanyl Buccal Tablet (FBT) in the Management of Breakthrough Pain. Donald R. Taylor, MD<sup>1</sup>; John Messina, PharmD<sup>2</sup>; Fang Xie, PhD<sup>2</sup>; Lynn R. Webster, MD

All the best,  
Helen

*Helen Yeh, PhD*  
*Director, Medical Communications*  
*Cephalon Inc*  
*41 Moores Road*  
*Frazer*  
*PA 19356*  
[hyeh@cephalon.com](mailto:hyeh@cephalon.com)  
*Tel: +1 610 883 5972*